Semarion is a University of Cambridge spin-out from the Cavendish Laboratory developing next-generation tools to accelerate cell-based drug discovery. Its proprietary SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models, increase throughput, and generate richer datasets using existing tools and workflows. Semarion is combining materials engineering, microfabrication, and cell biology to remove bottlenecks in adherent cell assays and unlock 10x gains in data generation.
Semarion: Venture Capital Funding History
Semarion
Semarion
- Life Sciences
- Cambridge, United Kingdom
- £2.9m
- semarion.com
- Update Information
More venture news
- 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 10 Nov 2026

Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026

PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences
